Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study - Concepedia

Concepedia

Publication | Closed Access

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

10

Citations

11

References

2024

Year

Julie N. Graff, Christopher Hoimes, Winald R. Gerritsen, Ulka N. Vaishampayan, Tony Elliott, Clara Hwang, Albert J. ten Tije, Aurelius Omlin, Ray McDermott, Yves Fradet,

Prostate Cancer and Prostatic Diseases

References

	Year	Citations

Page 1